#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Semaglutide optic neuropathy: correction
JCEM Case Reports issued a formal correction in July 2026 to a May 2026 case report on optic nerve injury after semaglutide escalation.
Tirzepatide: PERCEPTIONS survey findings
The PERCEPTIONS survey (n=518, US) found health improvement was the top reason patients started tirzepatide; cost and insurance were the main barriers.
Mounjaro on X: who shapes the conversation
A 2026 study of 5,566 Mounjaro tweets found that the top influencers on X are patients and public figures, not clinicians.
Semaglutide alters NAc oscillations in mice
Molecular Brain (July 2026) finds semaglutide changes nucleus accumbens oscillations and reward behaviour in healthy mice, not just in metabolic disease models.
Hengrui HRS-7535 oral GLP-1: Phase 3 data
Hengrui and Kailera reported Phase 3 results for HRS-7535, an oral GLP-1 drug, in July 2026. Here is what the peer-reviewed Phase 2 data shows.
Semaglutide and bilateral NAION
A July 2026 case report describes bilateral NAION and branch retinal artery occlusion in a man on semaglutide, with partial visual recovery after stopping.
Semaglutide: dose predicts CV outcomes
A July 2026 study found semaglutide's heart benefits track dose more closely than weight loss.
GLP-1 drugs: fewer falls in older adults
Semaglutide and tirzepatide were associated with roughly half the femoral fracture rate versus DPP-4 inhibitors in older adults with type 2 diabetes.
Tirzepatide vs semaglutide: JASSO subgroup
SURMOUNT-5 subgroup: tirzepatide cut body weight by 20.1% vs 12.9% for semaglutide in 383 adults meeting Japan obesity disease criteria.
Why Dr. Reddy's paused generic semaglutide
Dr. Reddy's paused generic semaglutide after flagging an API quality issue. Here is what that means for patients, prescribers, and the generic GLP-1 market.
GLP-1 drugs, menstrual changes: FAERS 2026
A July 2026 FAERS study found semaglutide carries broader menstrual signals than tirzepatide or liraglutide, but the data cannot establish causation.
How GLP-1 guides bone marrow stem cells
A July 2026 study shows GLP-1 steers bone marrow stem cells toward bone via HIF-2 and AKT, protecting bone in glucocorticoid-treated mice.